MedTrace Logo

Efficacy and Safety of CD5024 1% in Acne Vulgaris

NCT03034460 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-12-11

Study results available
· View outcomes & findings →

Summary

Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.

Conditions

Interventions

DRUG

CD5024 1% cream

500 µL on half-face, five days a week during 6 weeks

DRUG

CD5024 cream placebo

500 µL on half-face, five days a week during 6 weeks

DRUG

CD0271/CD1579 gel

500 µL on half-face, five days a week during 6 weeks

DRUG

CD0271/CD1579 gel placebo

500 µL on half-face, five days a week during 6 weeks

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-25
Primary Completion
2016-11-02
Completion
2016-11-02

Countries

  • Canada
  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03034460 on ClinicalTrials.gov